Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Avasopasem manganese - Galera Therapeutics

Next Previous
Drug Profile

Avasopasem manganese - Galera Therapeutics

Alternative Names: Avasopasem; GC 4419

Latest Information Update: 03 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Galera Therapeutics
  • Class Anti-inflammatories; Antifibrotics; Antineoplastics; Aza compounds; Chemoprotectants; Cyclohexanes; Pyridines; Small molecules
  • Mechanism of Action Antioxidants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II HER2 negative breast cancer
  • Suspended COVID 2019 infections; Head and neck cancer; Mucositis; Oesophagitis; Pancreatic cancer; Stomatitis; Unspecified
  • Discontinued Fibrosis

Most Recent Events

  • 03 Jan 2025 Phase-Ib/IIa clinical trials in HER2- negative breast cancer (Metastatic disease, Combination therapy) in USA (unspecified route) (Galera Therapeutics pipeline, January 2025)
  • 31 Dec 2024 Galera Therapeutics plans a clinical trial for HER2- negative breast cancer (Second-line therapy or greater, Late-stage disease) in first half of 2025
  • 28 Mar 2024 Suspended - Clinical-Phase-Unknown for Renal failure in USA (IV) prior to March 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top